 [1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes MINOCYCLINE increase or decrease the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does MINOCYCLINE increase the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes MINOCYCLINE increase the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes MINOCYCLINE increase the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does MINOCYCLINE increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"MINOCYCLINE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: MINOCYCLINE: adverse_reactions: Table [0m[1;31m2[0m[31m: Selected Treatment-Emergent Adverse Reactions in at least [0m[1;31m1[0m[31m% of Clinical Trial Subjects Adverse Reactions Minocycline Hydrochloride Extended-Release [0m
[31mTablets [0m[1;31m([0m[1;31m1[0m[31m mg/kg[0m[1;31m)[0m[31m [0m[31mN[0m[31m=[0m[1;31m674[0m[1;31m([0m[31m%[0m[1;31m)[0m[31m Placebo [0m[31mN[0m[31m=[0m[1;31m364[0m[1;31m([0m[31m%[0m[1;31m)[0m[31m At least one treatment-emergent event [0m[1;31m379[0m[1;31m([0m[1;31m56[0m[1;31m)[0m[31m [0m[1;31m197[0m[1;31m([0m[1;31m54[0m[1;31m)[0m[31m Headache [0m[1;31m152[0m[31m [0m[1;31m([0m[1;31m23[0m[1;31m)[0m[31m [0m[1;31m83[0m[31m [0m[1;31m([0m[1;31m23[0m[1;31m)[0m[31m Fatigue [0m[1;31m62[0m[31m [0m[1;31m([0m[1;31m9[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m7[0m[1;31m)[0m[31m Dizziness [0m[1;31m59[0m[31m [0m[1;31m([0m[1;31m9[0m[1;31m)[0m[31m [0m[1;31m17[0m[31m [0m[1;31m([0m[1;31m5[0m[1;31m)[0m[31m Pruritus [0m[1;31m31[0m[31m [0m[1;31m([0m[1;31m5[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m Malaise[0m
[1;31m26[0m[31m [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m Mood alteration [0m[1;31m17[0m[31m [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m Somnolence [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m Urticaria [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m Tinnitus [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m Arthralgia [0m[1;31m9[0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m2[0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m MINOCYCLINE: adverse_reactions: Vertigo [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m Dry mouth [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m
[1;31m5[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m Myalgia [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m6.2[0m[31m Postmarketing Experience Adverse reactions that have been reported with minocycline hydrochloride use in a variety of indications include: Skin and hypersensitivity [0m
[31mreactions: fixed drug eruptions, balanitis, erythema multiforme, Stevens-Johnson syndrome, anaphylactoid purpura, photosensitivity, pigmentation of skin and mucous membranes, hypersensitivity [0m
[31mreactions, angioneurotic edema, anaphylaxis, DRESS syndrome [0m[31m. Autoimmune conditions: polyarthralgia, pericarditis, exacerbation of systemic lupus, pulmonary infiltrates with eosinophilia, transient [0m
[31mlupus-like syndrome. MINOCYCLINE: adverse_reactions: Central nervous system: pseudotumor cerebri, bulging fontanels in infants, decreased hearing. Endocrine: brown-black microscopic thyroid [0m
[31mdiscoloration, abnormal thyroid function. Oncology : thyroid cancer. Oral: glossitis, dysphagia, tooth discoloration. Gastrointestinal : enterocolitis, pancreatitis, hepatitis, liver failure. Renal : [0m
[31mreversible acute renal failure. Hematology : hemolytic anemia, thrombocytopenia, eosinophilia. Preliminary studies suggest that use of minocycline may have deleterious effects on human spermatogenesis[0m
[31m.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: use_in_specific_populations: [0m[1;31m8[0m[31m USE IN SPECIFIC POPULATIONS • Minocycline like other tetracycline-class drugs can cause fetal harm when administered to a pregnant woman. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m , [0m
[1;31m8.1[0m[31m [0m[1;31m)[0m[31m • The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of teeth. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m , [0m[1;31m8.4[0m[31m [0m[1;31m)[0m[31m [0m[1;31m8.1[0m[31m Pregnancy Teratogenic Effects: Pregnancy Category D [0m[1;31m[[0m[31m see [0m
[31mWARNINGS AND PRECAUTIONS [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Minocycline hydrochloride extended-release tablets should not be used during pregnancy. If the patient becomes pregnant while taking this drug, the patient should be [0m
[31mapprised of the potential hazard to the fetus and stop treatment immediately. There are no adequate and well-controlled studies on the use of minocycline in pregnant women. MINOCYCLINE: [0m
[31muse_in_specific_populations: Minocycline, like other tetracycline-class drugs, crosses the placenta and may cause fetal harm when administered to a pregnant woman. Rare spontaneous reports of [0m
[31mcongenital anomalies including limb reduction have been reported with minocycline use in pregnancy in post-marketing experience. Only limited information is available regarding these reports; [0m
[31mtherefore, no conclusion on causal association can be established. Minocycline induced skeletal malformations [0m[1;31m([0m[31mbent limb bones[0m[1;31m)[0m[31m in fetuses when administered to pregnant rats and rabbits in doses of [0m[1;31m30[0m
[31mmg/kg/day and [0m[1;31m100[0m[31m mg/kg/day, respectively, [0m[1;31m([0m[31mresulting in approximately [0m[1;31m3[0m[31m times and [0m[1;31m2[0m[31m times, respectively, the systemic exposure to minocycline observed in patients as a result of use of minocycline [0m
[31mhydrochloride extended-release tablets[0m[1;31m)[0m[31m. MINOCYCLINE: use_in_specific_populations: Reduced mean fetal body weight was observed in studies in which minocycline was administered to pregnant rats at a [0m
[31mdose of [0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mwhich resulted in approximately the same level of systemic exposure to minocycline as that observed in patients who use minocycline hydrochloride extended-release tablets[0m[1;31m)[0m[31m. [0m
[31mMinocycline was assessed for effects on peri-and post-natal development of rats in a study that involved oral administration to pregnant rats from day [0m[1;31m6[0m[31m of gestation through the period of lactation [0m
[1;31m([0m[31mpostpartum day [0m[1;31m20[0m[1;31m)[0m[31m, at dosages of [0m[1;31m5[0m[31m, [0m[1;31m10[0m[31m, or [0m[1;31m50[0m[31m mg/kg/day. In this study, body weight gain was significantly reduced in pregnant females that received [0m[1;31m50[0m[31m mg/kg/day [0m[1;31m([0m[31mresulting in approximately [0m[1;31m2.5[0m[31m [0m
[31mtimes the systemic exposure to minocycline observed in patients as a result of use of minocycline hydrochloride extended-release tablets[0m[1;31m)[0m[31m. MINOCYCLINE: use_in_specific_populations: No effects of [0m
[31mtreatment on the duration of the gestation period or the number of live pups born per litter were observed. Gross external anomalies observed in F1 pups [0m[1;31m([0m[31moffspring of animals that received [0m
[31mminocycline[0m[1;31m)[0m[31m included reduced body size, improperly rotated forelimbs, and reduced size of extremities. No effects were observed on the physical development, behavior, learning ability, or [0m
[31mreproduction of F1 pups, and there was no effect on gross appearance of F2 pups [0m[1;31m([0m[31moffspring of F1 animals[0m[1;31m)[0m[31m. [0m[1;31m8.3[0m[31m Nursing Mothers Tetracycline-class antibiotics are excreted in human milk. Because of the[0m
[31mpotential for serious adverse effects on bone and tooth development in nursing infants from the tetracycline-class antibiotics, a decision should be made whether to discontinue nursing or discontinue [0m
[31mthe drug, taking into account the importance of the drug to the mother [0m[31m. [0m[1;31m8[0m[31m.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: spl_id         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: information_for_patients: [0m[1;31m17[0m[31m PATIENT COUNSELING INFORMATION [0m[1;31m[[0m[31mSee FDA-approved patient labeling [0m[1;31m([0m[31mPatient Information[0m[1;31m)[0m[1;31m][0m[31m Patients taking minocycline hydrochloride extended-release [0m
[31mtablets should receive the following information and instructions: • Minocycline hydrochloride extended-release tablets should not be used by pregnant women or women attempting to conceive a child [0m[31m. •[0m
[31mIt is recommended that minocycline hydrochloride extended-release tablets not be used by men who are attempting to father a child [0m[31m. • Patients should be advised that pseudomembranous colitis can occur[0m
[31mwith minocycline therapy. If patients develop watery or bloody stools, they should seek medical attention. • Patients should be counseled about the possibility of hepatotoxicity. MINOCYCLINE: [0m
[31minformation_for_patients: Patients should seek medical advice if they experience symptoms which can include loss of appetite, tiredness, diarrhea, skin turning yellow, bleeding easily, confusion, and [0m
[31msleepiness. • Patients who experience central nervous system symptoms [0m[31m should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy. Patients should seek [0m
[31mmedical help for persistent headaches or blurred vision. • Concurrent use of tetracycline may render oral contraceptives less effective [0m[31m. • Autoimmune syndromes, including drug-induced lupus-like [0m
[31msyndrome, autoimmune hepatitis, vasculitis and serum sickness have been observed with tetracycline-class drugs, including minocycline. Symptoms may be manifested by arthralgia, fever, rash and [0m
[31mmalaise. Patients who experience such symptoms should be cautioned to stop the drug immediately and seek medical help. MINOCYCLINE: information_for_patients: • Patients should be counseled about [0m
[31mdiscoloration of skin, scars, teeth or gums that can arise from minocycline therapy. • Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking [0m
[31mtetracyclines, including minocycline. Patients should minimize or avoid exposure to natural or artificial sunlight [0m[1;31m([0m[31mtanning beds or UVA/B treatment[0m[1;31m)[0m[31m while using minocycline. If patients need to be [0m
[31moutdoors while using minocycline, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician. Treatment should be [0m
[31mdiscontinued at the first evidence of skin erythema. • Minocycline hydrochloride extended-release tablets should be taken exactly as directed. Skipping doses or not completing the full course of [0m
[31mtherapy may decrease the effectiveness of the current treatment course and increase the likelihood that bacteria will develop resistance and will not be treatable by other antibacterial drugs in the [0m
[31mfuture. MINOCYCLINE: information_for_patients: • Patients should be advised to swallow minocycline hydrochloride extended-release tablets whole and not to chew, crush, or split the tablets.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: spl_set_id         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: spl_patient_package_insert: See “What should I tell my doctor before taking minocycline hydrochloride extended-release tablets?” • Intestine infection [0m[1;31m([0m[31mpseudomembranous colitis[0m[1;31m)[0m[31m.[0m
[31mPseudomembranous colitis can happen with most antibiotics, including minocycline hydrochloride extended-release tablets. Call your doctor right away if you get watery diarrhea, diarrhea that does not [0m
[31mgo away, or bloody stools. • Serious liver problems . Stop taking minocycline hydrochloride extended-release tablets and call your doctor right away if you get any of the following symptoms of liver [0m
[31mproblems: ∘ loss of appetite ∘ tiredness ∘ diarrhea ∘ yellowing of your skin or the whites of your eyes ∘ unexplained bleeding ∘ confusion ∘ sleepiness • Central nervous system effects. See “What [0m
[31mshould I avoid while taking minocycline hydrochloride extended-release tablets? MINOCYCLINE: spl_patient_package_insert: Central nervous system effects such as light headedness, dizziness, and a [0m
[31mspinning feeling [0m[1;31m([0m[31mvertigo[0m[1;31m)[0m[31m may go away during your treatment with minocycline hydrochloride extended-release tablets or if treatment is stopped. • Benign intracranial hypertension, also called [0m
[31mpseudotumor cerebri . This is a condition where there is high pressure in the fluid around the brain. This swelling may lead to vision changes and permanent vision loss. Stop taking minocycline [0m
[31mhydrochloride extended-release tablets and tell your doctor right away if you have blurred vision, vision loss, or unusual headaches. Immune system reactions including a lupus-like syndrome, [0m
[31mhepatitis, and inflammation of blood or lymph vessels [0m[1;31m([0m[31mvasculitis[0m[1;31m)[0m[31m. Using minocycline hydrochloride extended-release tablets for a long time to treat acne may cause immune system reactions. Tell your [0m
[31mdoctor right away if you get a fever, rash, joint pain, or body weakness. MINOCYCLINE: spl_patient_package_insert: Your doctor may do tests to check your blood for immune system reactions. • Serious [0m
[31mrash and allergic reactions . Minocycline hydrochloride extended-release tablets may cause a serious rash and allergic reactions that may affect parts of your body such as your liver, lungs, kidneys [0m
[31mand heart. Sometimes these can lead to death. MINOCYCLINE: spl_patient_package_insert: • Stop taking minocycline hydrochloride extended-release tablets and get medical help right away if you have any [0m
[31mof these symptoms: ∘ skin rash, hives, sores in your mouth, or your skin blisters and peels ∘ swelling of your face, eyes, lips, tongue, or throat ∘ trouble swallowing or breathing ∘ blood in your [0m
[31murine ∘ fever, yellowing of the skin or the whites of your eyes, dark colored urine ∘ pain on the right side of the stomach area [0m[1;31m([0m[31mabdominal pain[0m[1;31m)[0m[31m ∘ chest pain or abnormal heartbeats ∘ swelling in your[0m
[31mlegs, ankles and feet ∘ darkening of your nails, skin, eyes, scars, teeth, and gums. The most common side effects of minocycline hydrochloride extended-release tablets include: • headache • tiredness [0m
[31m• dizziness or spinning feeling • itching Call your doctor if you have a side effect that bothers you or that does not go away. MINOCYCLINE: spl_patient_package_insert: Your doctor may do tests to [0m
[31mcheck you for side effects during treatment with minocycline hydrochloride extended-release tablets. These are not all the side effects with minocycline hydrochloride extended-release tablets. Ask [0m
[31myour doctor or pharmacist for more information. Call your doctor for medical advice about side effects. You may report side effects to Sandoz Inc. at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m525[0m[31m-[0m[1;31m8747[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m. How [0m
[31mshould I store minocycline hydrochloride extended-release tablets? • Store minocycline hydrochloride extended-release tablets at 20º to 25ºC [0m[1;31m([0m[31m68º to 77ºF[0m[1;31m)[0m[31m [0m[31m. • Keep minocycline hydrochloride [0m
[31mextended-release tablets in the container that it comes in and keep container tightly closed. • Keep minocycline hydrochloride extended-release tablets dry.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: carcinogenesis_and_mutagenesis_and_impairment_of_fertility: [0m[1;31m13.1[0m[31m Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis In a carcinogenicity study in which [0m
[31mminocycline HCl was orally administered to male and female rats once daily for up to [0m[1;31m104[0m[31m weeks at dosages up to [0m[1;31m200[0m[31m mg/kg/day, minocycline HCl was associated in both genders with follicular cell [0m
[31mtumors of the thyroid gland, including increased incidences of adenomas, carcinomas and the combined incidence of adenomas and carcinomas in males, and adenomas and the combined incidence of adenomas [0m
[31mand carcinomas in females. In a carcinogenicity study in which minocycline HCl was orally administered to male and female mice once daily for up to [0m[1;31m104[0m[31m weeks at dosages up to [0m[1;31m150[0m[31m mg/kg/day, exposure [0m
[31mto minocycline HCl did not result in a significantly increased incidence of neoplasms in either males or females. MINOCYCLINE: carcinogenesis_and_mutagenesis_and_impairment_of_fertility: Mutagenesis [0m
[31mMinocycline was not mutagenic in vitro in a bacterial reverse mutation assay [0m[1;31m([0m[31mAmes test[0m[1;31m)[0m[31m or CHO/HGPRT mammalian cell assay in the presence or absence of metabolic activation. Minocycline was not [0m
[31mclastogenic in vitro using human peripheral blood lymphocytes or in vivo in a mouse micronucleus test. Impairment of Fertility Male and female reproductive performance in rats was unaffected by oral [0m
[31mdoses of minocycline of up to [0m[1;31m300[0m[31m mg/kg/day [0m[1;31m([0m[31mwhich resulted in up to approximately [0m[1;31m40[0m[31m times the level of systemic exposure to minocycline observed in patients as a result of use of minocycline [0m
[31mhydrochloride extended-release tablets[0m[1;31m)[0m[31m. MINOCYCLINE: carcinogenesis_and_mutagenesis_and_impairment_of_fertility: However, oral administration of [0m[1;31m100[0m[31m or [0m[1;31m300[0m[31m mg/kg/day of minocycline to male rats [0m
[1;31m([0m[31mresulting in approximately [0m[1;31m15[0m[31m to [0m[1;31m40[0m[31m times the level of systemic exposure to minocycline observed in patients as a result of use of minocycline hydrochloride extended-release tablets[0m[1;31m)[0m[31m adversely [0m
[31maffected spermatogenesis. Effects observed at [0m[1;31m300[0m[31m mg/kg/day included a reduced number of sperm cells per gram of epididymis, an apparent reduction in the percentage of sperm that were motile, and [0m[1;31m([0m[31mat [0m
[1;31m100[0m[31m and [0m[1;31m300[0m[31m mg/kg/day[0m[1;31m)[0m[31m increased numbers of morphologically abnormal sperm cells. Morphological abnormalities observed in sperm samples included absent heads, misshapen heads, and abnormal flagella. [0m
[31mLimited human studies suggest that minocycline may have a deleterious effect on spermatogenesis. Minocycline hydrochloride extended-release tablets should not be used by individuals of either gender [0m
[31mwho are attempting to conceive a child.         [0m
[31mSOURCE:MINOCYCLINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The provided extracts from the MINOCYCLINE label do not mention an increased risk of aplastic anemia specifically. The adverse reactions reported with minocycline use in clinical trials and [0m
[32mpostmarketing experience include various hematological issues such as hemolytic anemia, thrombocytopenia, and eosinophilia, but aplastic anemia is not listed among them.[0m

[32mSOURCE: MINOCYCLINE label[0m
[32mEXTRACT_START_END: Hematology: hemolytic anemia, thrombocytopenia, eosinophilia[0m[32m...[0m
*[1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The provided extracts from the MINOCYCLINE label do not [0m
[34mmention an increased risk of aplastic anemia specifically. The adverse reactions reported with minocycline use in clinical trials and postmarketing experience include various hematological issues such[0m
[34mas hemolytic anemia, thrombocytopenia, and eosinophilia, but aplastic anemia is not listed among them.[0m

[34mSOURCE: MINOCYCLINE label[0m
[34mEXTRACT_START_END: Hematology: hemolytic anemia, thrombocytopenia, eosinophilia[0m[34m...[0m
 [1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mThe FDA label for MINOCYCLINE does not specifically mention an [0m
[32mincreased risk of aplastic anemia. While the label does list various hematological issues such as hemolytic anemia, thrombocytopenia, and eosinophilia as adverse reactions reported in clinical trials [0m
[32mand postmarketing experience, aplastic anemia is not included among them.[0m

[32mTherefore, based on the information provided by the FDA label, it cannot be concluded that MINOCYCLINE increases the risk of aplastic anemia. The absence of this condition in the label suggests that [0m
[32meither it has not been reported with sufficient frequency or evidence to warrant inclusion, or it has not been observed at all in association with MINOCYCLINE use.[0m

[32mFinal Answer: Does MINOCYCLINE increase or decrease the risk of aplastic anemia?[0m

[32mBased on the FDA label data, there is no information to suggest that MINOCYCLINE increases the risk of aplastic anemia.[0m
 [1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [31m Entity.USER [0m
*[1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m          [1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Do one of the following:[0m

[31m        [0m[1;31m1[0m[31m. If you intend to ask a question to FDAAgent:[0m
[31m            Please use the [0m[31m'add_recipient'[0m[31m tool/function-call[0m
[31m            and specify FDAAgent as your `intended_recipient`.[0m
[31m            DO NOT REPEAT your original message; ONLY specify the [0m
[31m            `intended_recipient` via this tool/function-call.[0m
[31m        [0m[1;31m2[0m[31m. If you are ready to have the critic check your answer,[0m
[31m            do so with the `final_answer` tool/function, as I have requested.[0m
[31m        [0m[1;31m3[0m[31m. If the critic is satisfied and you intend to submit your final answer,[0m
[31m            answer as I have requested, making sure to mark that you are done as usual.[0m

[31m        When you have decided and stated your answer [0m[1;31m([0m[31mor lack of one[0m[1;31m)[0m[31m, you must[0m
[31m        ALWAYS specify that you are done using the usual code.[0m

[31m        DO NOT simply acknowldedge these instructions. If you have nothing[0m
[31m        else to say, you MUST EXIT IMMEDIATELY by stating that you are done[0m
[31m        with the usual code [0m[1;31m([0m[31mas in #[0m[1;31m3[0m[1;31m)[0m[31m.[0m
[31m        [0m
 [1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does MINOCYCLINE increase or decrease the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether MINOCYCLINE increases the risk of aplastic anemia."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the MINOCYCLINE label does not mention an increased risk of aplastic anemia specifically. It lists various hematological issues such as hemolytic anemia, [0m
[32mthrombocytopenia, and eosinophilia as adverse reactions, but aplastic anemia is not included among them."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"Based on the FDA label data, there is no information to suggest that MINOCYCLINE increases the risk of aplastic anemia."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does MINOCYCLINE increase or decrease the risk of aplastic anemia?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether MINOCYCLINE increases the risk of aplastic anemia."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the MINOCYCLINE label does not mention an increased risk of aplastic anemia specifically. It lists various hematological issues such as hemolytic anemia, [0m
[34mthrombocytopenia, and eosinophilia as adverse reactions, but aplastic anemia is not included among them."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"Based on the FDA label data, there is no information to suggest that MINOCYCLINE increases the risk of aplastic anemia."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does MINOCYCLINE increase or decrease the risk of aplastic anemia?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether MINOCYCLINE increases the risk of aplastic anemia.[0m
[1;31m2[0m[31m. FDAHandler responded that the MINOCYCLINE label does not mention an increased risk of aplastic anemia specifically. It lists various hematological issues such as hemolytic anemia, thrombocytopenia,[0m
[31mand eosinophilia as adverse reactions, but aplastic anemia is not included among them.[0m
[31m        -----[0m
[31m        Final answer: Based on the FDA label data, there is no information to suggest that MINOCYCLINE increases the risk of aplastic anemia.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mFinal Answer: Does MINOCYCLINE increase or decrease the risk of aplastic anemia?[0m

[32mBased on the FDA label data, there is no information to suggest that MINOCYCLINE increases the risk of aplastic anemia. The label lists various hematological issues as adverse reactions, but aplastic [0m
[32manemia is not included among them.[0m
